Here are three reasons why Pfizer could prove to be a steal of a deal this year. Buying quality stocks at decent valuations ...

We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other most ...

We recently published a list of 10 Stocks Market Experts are Talking About These Days. In this article, we are going to take ...

The company aims to start a Phase 2 trial for PRX-115 in 2025. Vandana Singh Pfizer's Direct-To-Consumer Model Faces Scrutiny From US Senators (CORRECTED) Senators question Pfizer's partnership ...

Pfizer’s PFE stock has risen 5.9% in the past three months. The stock has started to show a consistent increase, with some ups and downs in between, after it took a hammering in the past couple ...

At the time I argued that Pfizer's projected EPS growth and anticipated rise in EBITDA margins suggested a positive trajectory for the stock price, so seeing a 20%+ upside from those levels ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

In addition to reducing Pfizer's net debt by $4.65 billion over the past 12 months, you'll learn why I believe it is an attractive stock for income-oriented investors. Pfizer, under the leadership ...

Pfizer Inc. shares fell 2% Tuesday despite the drugmaker topping Wall Street’s revenue and profit estimates in its fourth-quarter results. Analyst firm Edward Jones expects Pfizer’s future ...